#BEGIN_DRUGCARD DB00167

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Absorbed from the small intestine by a sodium-dependent active-transport process

# Biotransformation:
Hepatic

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
73-32-5

# ChEBI_ID:
17191

# Chemical_Formula:
C6H13NO2

# Chemical_IUPAC_Name:
(2S,3S)-2-amino-3-methylpentanoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of leucine. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels. [PubChem]

# Dosage_Forms:
Capsule	Oral
Powder	Oral
Tablet	Oral

# Drug_Category:
Dietary supplement
Essential Amino Acids
Micronutrient

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Nutraceutical
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-1.70

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
3.44E+004 mg/L (at 25 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
L-Isoleucine

# HET_ID:
ILE

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C6H13NO2/c1-3-4(2)5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t4-,5-/m0/s1

# InChI_Key:
InChIKey=AGPKZVBTJJNPAG-WHFBIAKZSA-N

# Indication:
The branched-chain amino acids may have antihepatic encephalopathy activity in some. They may also have anticatabolic and antitardive dyskinesia activity.

# KEGG_Compound_ID:
C00407

# KEGG_Drug_ID:
D00065

# LIMS_Drug_ID:
167

# Mechanism_Of_Action:
(Applies to Valine, Leucine and Isoleucine) <br/>This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. <br/>The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. <br/>There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS.

# Melting_Point:
285.5 dec °C

# Molecular_Weight_Avg:
131.1729

# Molecular_Weight_Mono:
131.094628665

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1H74

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/bra_0042.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA164750430

# Pharmacology:
They provide ingredients for the manufacturing of other essential biochemical components in the body, some of which are utilized for the production of energy, stimulants to the upper brain and helping you to be more alert.

# Predicted_LogP_Hydrophobicity:
-1.7

# Predicted_LogS:
-0.06

# Predicted_Water_Solubility:
1.14e+02 g/l

# Primary_Accession_No:
DB00167

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
6306

# PubChem_Substance_ID:
46506864

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
NUTR00031

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC[C@H](C)[C@H](N)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
(2S,3S)-2-Amino-3-methylpentanoic acid
(2S,3S)-a-Amino-b-methyl-n-valeric acid
(2S,3S)-a-Amino-b-methylvaleric acid
(S)-Isoleucine
(S,S)-Isoleucine
2-Amino-3-methylvaleric acid
2S,3S-Isoleucine
Isoleucine
L-(+)-Isoleucine
L-Ile
erythro-L-Isoleucine

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of hypoglycemia, increased mortality in ALS patients taking large doses of BCAAs

# Update_Date:
2013-02-08 16:19:09 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
2.37 (at 0 °C)

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
5111605	Kedzierski W, Pawelkiewicz J: Interaction of lupin isoleucine-tRNA synthetase with isoleucine transfer ribonucleic acid measured by the thermal inactivation method. Acta Biochim Pol. 1971;18(2):153-61.
8129874	Schimmel P, Landro JA, Schmidt E: Evidence for distinct locations for metal binding sites in two closely related class I tRNA synthetases. J Biomol Struct Dyn. 1993 Dec;11(3):571-81.
8146659	Schmidt E, Schimmel P: Mutational isolation of a sieve for editing in a transfer RNA synthetase. Science. 1994 Apr 8;264(5156):265-7.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
IARS

# Drug_Target_1_GenBank_ID_Gene:
AL136097

# Drug_Target_1_GenBank_ID_Protein:
55957316

# Drug_Target_1_GeneCard_ID:
IARS

# Drug_Target_1_Gene_Name:
IARS

# Drug_Target_1_Gene_Sequence:
>990 bp
ATGCTTCAACAAGTTCCAGAAAACATAAATTTTCCTGCTGAAGAAGAGAAAATCTTGGAG
TTTTGGACTGAATTTAATTGTTTTCAGGAATGCTTAAAGCAATCAAAACATAAACCAAAA
TTTACCTTCTATGATGGTCCTCCTTTTGCAACTGGACTGCCTCACTATGGACATATACTT
GCGGGTACAATTAAAGATATAGTTACAAGATATGCTCACCAGAGTGGGTTTCATGTTGAC
AGAAGATTTGGATGGGATTGCCATGGCTTACCTGTGGAATATGAAATTGATAAGACACTG
GGAATCAGAGGACCAGAGGATGTGGCCAAAATGGGGATTACAGAGTATAACAATCAGTGC
CGAGCAATTGTGATGAGATATTCTGCTGAGTGGAAGTCTACTGTTAGCAGACTTGGCCGA
TGGATTGACTTTGACAATGACTATAAAACTCTGTATCCACAATTCATGGAATCAGTCTGG
TGGGTCTTCAAACAACTCTATGATAAAGGCCTTGTTTATAGAGGTGTGAAAGTCATGCCC
TTCTCTACGGCATGTAACACTCCACTTTCCAACTTCGAGTCACACCAGAATTATAAGGAT
GTTCAAGATCCTTCAGTATTTGTAACTTTCCCTTTGGAAGAAGATGAAACTGTATCTTTA
GTTGCTTGGACAACCACTCCCTGGACTCTACCTAGTAACCTTGCTGTGTGTGTTAATCCA
GAAATGCAATATGTGAAAATTAAAGATGTTGCCAGAGGACGATTACTCATTTTAATGGAA
GCCAGATTGTCAGCCCTCTATAAATTGGAGAGTGACTATGAGATCCTTGAAAGATTTCCT
GGTGCCTATCTTAAAGGCAAGAAGTACAGGCCCCTGTTTGACTATTTCCTGAAGTGTAAA
GAGAATGGCGCTTTCACTGTGCTTGTTGACAACTATGTGAAGGAAGAAGAAGGCACAGGG
GTTGTCCACCAAGCTCCTTACTTCGGTGCT

# Drug_Target_1_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
HGNC:5330

# Drug_Target_1_HPRD_ID:
02832

# Drug_Target_1_ID:
701

# Drug_Target_1_Locus:
9q21

# Drug_Target_1_Molecular_Weight:
38344

# Drug_Target_1_Name:
Isoleucine-tRNA synthetase

# Drug_Target_1_Number_of_Residues:
330

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00133	tRNA-synt_1

# Drug_Target_1_Protein_Sequence:
>Isoleucine-tRNA synthetase
MLQQVPENINFPAEEEKILEFWTEFNCFQECLKQSKHKPKFTFYDGPPFATGLPHYGHIL
AGTIKDIVTRYAHQSGFHVDRRFGWDCHGLPVEYEIDKTLGIRGPEDVAKMGITEYNNQC
RAIVMRYSAEWKSTVSRLGRWIDFDNDYKTLYPQFMESVWWVFKQLYDKGLVYRGVKVMP
FSTACNTPLSNFESHQNYKDVQDPSVFVTFPLEEDETVSLVAWTTTPWTLPSNLAVCVNP
EMQYVKIKDVARGRLLILMEARLSALYKLESDYEILERFPGAYLKGKKYRPLFDYFLKCK
ENGAFTVLVDNYVKEEEGTGVVHQAPYFGA

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q5TCD1

# Drug_Target_1_SwissProt_Name:
Q5TCD1_HUMAN

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
6.11

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Mitochondrion

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
12783542	Wang P, Tang Y, Tirrell DA: Incorporation of trifluoroisoleucine into proteins in vivo. J Am Chem Soc. 2003 Jun 11;125(23):6900-6.
14672940	Fukunaga R, Fukai S, Ishitani R, Nureki O, Yokoyama S: Crystal structures of the CP1 domain from Thermus thermophilus isoleucyl-tRNA synthetase and its complex with L-valine. J Biol Chem. 2004 Feb 27;279(9):8396-402. Epub 2003 Dec 12.
15663927	Fukunaga R, Yokoyama S: Crystal structure of leucyl-tRNA synthetase from the archaeon Pyrococcus horikoshii reveals a novel editing domain orientation. J Mol Biol. 2005 Feb 11;346(1):57-71. Epub 2004 Dec 19.
16697013	Fukunaga R, Yokoyama S: Structural basis for substrate recognition by the editing domain of isoleucyl-tRNA synthetase. J Mol Biol. 2006 Jun 16;359(4):901-12. Epub 2006 Apr 25.
17095543	Zhu B, Zhao MW, Eriani G, Wang ED: A present-day aminoacyl-tRNA synthetase with ancestral editing properties. RNA. 2007 Jan;13(1):15-21. Epub 2006 Nov 9.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
IARS2

# Drug_Target_2_GenBank_ID_Gene:
AC103590

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
IARS2

# Drug_Target_2_Gene_Name:
IARS2

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
HGNC:29685

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
4080

# Drug_Target_2_Locus:
1q41

# Drug_Target_2_Molecular_Weight:
113793

# Drug_Target_2_Name:
Isoleucyl-tRNA synthetase, mitochondrial

# Drug_Target_2_Number_of_Residues:
1012

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00133	tRNA-synt_1
PF06827	zf-FPG_IleRS
PF08264	Anticodon_1

# Drug_Target_2_Protein_Sequence:
>Isoleucyl-tRNA synthetase, mitochondrial
MRWGLRPRGPGAAALATARSLWGTPRLPCSPGWQGATKRLLVRSVSGASNHQPNSNSGRY
RDTVLLPQTSFPMKLLGRQQPDTELEIQQKCGFSELYSWQRERKVKTEFCLHDGPPYANG
DPHVGHALNKILKDIANRFHMMNGSKIHFVPGWDCHGLPIEIKVLSELGREAQNLSAMEI
RKKARSFAKAAIEKQKSAFIRWGIMADWNNCYYTFDGKYEAKQLRTFYQMYDKGLVYRSY
KPVFWSPSSRTALAEAELEYNPEHVSRSIYVKFPLLKPSPKLASLIDGSSPVSILVWTTQ
PWTIPANEAVCYMPESKYAVVKCSKSGDLYVLAADKVASVASTLETTFETISTLSGVDLE
NGTCSHPLIPDKASPLLPANHVTMAKGTGLVHTAPAHGMEDYGVASQHNLPMDCLVDEDG
VFTDVAGPELQNKAVLEEGTDVVIKMLQTAKNLLKEEKLVHSYPYDWRTKKPVVIRASKQ
WFINITDIKTAAKELLKKVKFIPGSALNGMVEMMDRRPYWCISRQRVWGVPIPVFHHKTK
DEYLINSQTTEHIVKLVEQHGSDIWWTLPPEQLLPKEVLSEVGGPDALEYVPGQDILDIW
FDSGTSWSYVLPGPDQRADLYLEGKDQLGGWFQSSLLTSVAARKRAPYKTVIVHGFTLGE
KGEKMSKSLGNVIHPDVVVNGGQDQSKEPPYGADVLRWWVADSNVFTEVAIGPSVLNAAR
DDISKLRNTLRFLLGNVADFNPETDSIPVNDMYVIDQYMLHLLQDLANKITELYKQYDFG
KVVRLLRTFYTRELSNFYFSIIKDRLYCEKENDPKRRSCQTALVEILDVIVRSFAPILPH
LAEEVFQHIPYIKEPKSVFRTGWISTSSIWKKPGLEEAVESACAMRDSFLGSIPGKNAAE
YKVITVIEPGLLFEIIEMLQSEETSSTSQLNELMMASESTLLAQEPREMTADVIELKGKF
LINLEGGDIREESSYKVIVMPTTKEKCPRCWKYTAESSDTLCPRCAEVVSGK

# Drug_Target_2_Reaction:
ATP + L-isoleucine + tRNAIle = AMP + diphosphate + L-isoleucyl-tRNAIle

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
ATP + L-isoleucine + tRNA(Ile) = AMP + diphosphate + L-isoleucyl-tRNA(Ile)

# Drug_Target_2_SwissProt_ID:
Q9NSE4

# Drug_Target_2_SwissProt_Name:
SYIM_HUMAN

# Drug_Target_2_Synonyms:
EC 6.1.1.5
IleRS
Isoleucine--tRNA ligase
Isoleucyl-tRNA synthetase, mitochondrial precursor

# Drug_Target_2_Theoretical_pI:
7.20

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
15615815	Korman SH, Andresen BS, Zeharia A, Gutman A, Boneh A, Pitt JJ: 2-ethylhydracrylic aciduria in short/branched-chain acyl-CoA dehydrogenase deficiency: application to diagnosis and implications for the R-pathway of isoleucine oxidation. Clin Chem. 2005 Mar;51(3):610-7. Epub 2004 Dec 22.
16317551	Madsen PP, Kibaek M, Roca X, Sachidanandam R, Krainer AR, Christensen E, Steiner RD, Gibson KM, Corydon TJ, Knudsen I, Wanders RJ, Ruiter JP, Gregersen N, Andresen BS: Short/branched-chain acyl-CoA dehydrogenase deficiency due to an IVS3+3A>G mutation that causes exon skipping. Hum Genet. 2006 Feb;118(6):680-90. Epub 2005 Nov 30.
16950638	Korman SH: Inborn errors of isoleucine degradation: a review. Mol Genet Metab. 2006 Dec;89(4):289-99. Epub 2006 Sep 6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
ACADSB

# Drug_Target_3_GenBank_ID_Gene:
U12778

# Drug_Target_3_GenBank_ID_Protein:
531391

# Drug_Target_3_GeneCard_ID:
ACADSB

# Drug_Target_3_Gene_Name:
ACADSB

# Drug_Target_3_Gene_Sequence:
>1299 bp
ATGGAGGGCCTGGCAGTGCGGTTGCTGCGCGGCAGCAGGCTGCTAAGAAGAAATTTCCTG
ACTTGTTTGTCTTCTTGGAAGATTCCTCCTCATGTCTCAAAATCTTCCCAGTCAGAAGCT
CTACTCAATATAACAAATAATGGAATACACTTTGCTCCCCTGCAAACATTTACAGATGAG
GAAATGATGATAAAGAGTTCAGTTAAAAAATTTGCTCAGGAACAAATTGCACCTTTGGTT
TCAACCATGGATGAAAATTCGAAAATGGAGAAATCAGTAATACAAGGATTATTTCAACAA
GGGTTGATGGGTATTGAAGTTGACCCAGAATATGGAGGCACAGGAGCTTCTTTTTTATCC
ACTGTGCTCGTGATAGAGGAATTAGCCAAAGTTGATGCATCTGTGGCTGTCTTTTGTGAG
ATCCAGAACACATTAATTAACACACTGATTAGAAAACATGGAACAGAAGAACAAAAGGCC
ACCTATTTGCCTCAGCTCACTACAGAAAAAGTAGGAAGTTTCTGCCTTTCAGAGGCTGGA
GCAGGTAGTGACTCATTTGCTTTGAAGACCAGAGCTGATAAAGAGGGAGATTATTATGTC
CTCAATGGATCAAAGATGTGGATCAGCAGTGCTGAGCATGCAGGGCTCTTTCTGGTGATG
GCAAATGTAGACCCTACCATTGGATATAAGGGAATTACCTCCTTCTTAGTAGATCGTGAT
ACTCCGGGCCTTCATATAGGGAAACCTGAAAACAAATTGGGGCTCAGAGCTTCTTCCACC
TGCCCGTTAACATTCGAAAATGTCAAGGTTCCAGAAGCCAATATCTTGGGACAAATTGGA
CATGGCTATAAGTATGCCATAGGGAGTCTCAATGAAGGTAGAATAGGAATTGCTGCACAG
ATGCTGGGACTGGCGCAAGGATGTTTTGACTACACTATTCCATATATTAAAGAAAGGATA
CAATTTGGCAAAAGACTATTTGATTTTCAGGGCCTCCAACACCAAGTGGCTCACGTGGCC
ACCCAGCTGGAAGCTGCAAGATTACTAACATACAATGCTGCTAGGCTTTTAGAAGCTGGA
AAGCCATTCATAAAAGAAGCGTCAATGGCCAAATACTATGCATCAGAGATTGCAGGACAA
ACAACGAGTAAATGTATCGAGTGGATGGGGGGAGTAGGCTACACCAAAGATTACCCTGTG
GAGAAATACTTCCGAGATGCAAAGATTGGTACGATATATGAAGGAGCTTCCAACATCCAG
TTGAACACCATTGCAAAGCATATCGATGCAGAATACTGA

# Drug_Target_3_General_Function:
Lipid transport and metabolism

# Drug_Target_3_General_References:
10832746	Gibson KM, Burlingame TG, Hogema B, Jakobs C, Schutgens RB, Millington D, Roe CR, Roe DS, Sweetman L, Steiner RD, Linck L, Pohowalla P, Sacks M, Kiss D, Rinaldo P, Vockley J: 2-Methylbutyryl-coenzyme A dehydrogenase deficiency: a new inborn error of L-isoleucine metabolism. Pediatr Res. 2000 Jun;47(6):830-3.
11013134	Andresen BS, Christensen E, Corydon TJ, Bross P, Pilgaard B, Wanders RJ, Ruiter JP, Simonsen H, Winter V, Knudsen I, Schroeder LD, Gregersen N, Skovby F: Isolated 2-methylbutyrylglycinuria caused by short/branched-chain acyl-CoA dehydrogenase deficiency: identification of a new enzyme defect, resolution of its molecular basis, and evidence for distinct acyl-CoA dehydrogenases in isoleucine and valine metabolism. Am J Hum Genet. 2000 Nov;67(5):1095-103. Epub 2000 Sep 29.
7698750	Rozen R, Vockley J, Zhou L, Milos R, Willard J, Fu K, Vicanek C, Low-Nang L, Torban E, Fournier B: Isolation and expression of a cDNA encoding the precursor for a novel member (ACADSB) of the acyl-CoA dehydrogenase gene family. Genomics. 1994 Nov 15;24(2):280-7.

# Drug_Target_3_HGNC_ID:
HGNC:91

# Drug_Target_3_HPRD_ID:
02626

# Drug_Target_3_ID:
630

# Drug_Target_3_Locus:
10q26.13

# Drug_Target_3_Molecular_Weight:
47486

# Drug_Target_3_Name:
Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial

# Drug_Target_3_Number_of_Residues:
432

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00441	Acyl-CoA_dh_1
PF02770	Acyl-CoA_dh_M
PF02771	Acyl-CoA_dh_N

# Drug_Target_3_Protein_Sequence:
>Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial precursor
MEGLAVRLLRGSRLLRRNFLTCLSSWKIPPHVSKSSQSEALLNITNNGIHFAPLQTFTDE
EMMIKSSVKKFAQEQIAPLVSTMDENSKMEKSVIQGLFQQGLMGIEVDPEYGGTGASFLS
TVLVIEELAKVDASVAVFCEIQNTLINTLIRKHGTEEQKATYLPQLTTEKVGSFCLSEAG
AGSDSFALKTRADKEGDYYVLNGSKMWISSAEHAGLFLVMANVDPTIGYKGITSFLVDRD
TPGLHIGKPENKLGLRASSTCPLTFENVKVPEANILGQIGHGYKYAIGSLNEGRIGIAAQ
MLGLAQGCFDYTIPYIKERIQFGKRLFDFQGLQHQVAHVATQLEAARLLTYNAARLLEAG
KPFIKEASMAKYYASEIAGQTTSKCIEWMGGVGYTKDYPVEKYFRDAKIGTIYEGASNIQ
LNTIAKHIDAEY

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Has greatest activity toward short branched chain acyl- CoA derivative such as (s)-2-methylbutyryl-CoA, isobutyryl-CoA, and 2-methylhexanoyl-CoA as well as toward short straight chain acyl-CoAs such as butyryl-CoA and hexanoyl-CoA. Can use valproyl- CoA as substrate and may play a role in controlling the metabolic flux of valproic acid in the development of toxicity of this agent

# Drug_Target_3_SwissProt_ID:
P45954

# Drug_Target_3_SwissProt_Name:
ACDSB_HUMAN

# Drug_Target_3_Synonyms:
2-MEBCAD
2-methyl branched chain acyl-CoA dehydrogenase
2-methylbutyryl-CoA dehydrogenase
2-methylbutyryl-coenzyme A dehydrogenase
EC 1.3.99.-
SBCAD
Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial precursor

# Drug_Target_3_Theoretical_pI:
7.00

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Cytoplasm

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
12147502	Madsen SM, Beck HC, Ravn P, Vrang A, Hansen AM, Israelsen H: Cloning and inactivation of a branched-chain-amino-acid aminotransferase gene from Staphylococcus carnosus and characterization of the enzyme. Appl Environ Microbiol. 2002 Aug;68(8):4007-14.
12667063	Goto M, Miyahara I, Hayashi H, Kagamiyama H, Hirotsu K: Crystal structures of branched-chain amino acid aminotransferase complexed with glutamate and glutarate: true reaction intermediate and double substrate recognition of the enzyme. Biochemistry. 2003 Apr 8;42(13):3725-33.
14962140	Thage BV, Rattray FP, Laustsen MW, Ardo Y, Barkholt V, Houlberg U: Purification and characterization of a branched-chain amino acid aminotransferase from Lactobacillus paracasei subsp. paracasei CHCC 2115. J Appl Microbiol. 2004;96(3):593-602.
15667998	Beck HC: Branched-chain fatty acid biosynthesis in a branched-chain amino acid aminotransferase mutant of Staphylococcus carnosus. FEMS Microbiol Lett. 2005 Feb 1;243(1):37-44.
17554170	Chen CD, Huang TF, Lin CH, Guan HH, Hsieh YC, Lin YH, Huang YC, Liu MY, Chang WC, Chen CJ: Purification, crystallization and preliminary X-ray crystallographic analysis of branched-chain aminotransferase from Deinococcus radiodurans. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Jun 1;63(Pt 6):492-4. Epub 2007 May 5.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
BCAT1

# Drug_Target_4_GenBank_ID_Gene:
U21551

# Drug_Target_4_GenBank_ID_Protein:
1036780

# Drug_Target_4_GeneCard_ID:
BCAT1

# Drug_Target_4_Gene_Name:
BCAT1

# Drug_Target_4_Gene_Sequence:
>1155 bp
ATGGATTGCAGTAACGGATCGGCAGAGTGTACCGGAGAAGGAGGATCAAAAGAGGTGGTG
GGGACTTTTAAGGCTAAAGACCTAATAGTCACACCAGCTACCATTTTAAAGGAAAAACCA
GACCCCAATAATCTGGTTTTTGGAACTGTGTTCACGGATCATATGCTGACGGTGGAGTGG
TCCTCAGAGTTTGGATGGGAGAAACCTCATATCAAGCCTCTTCAGAACCTGTCATTGCAC
CCTGGCTCATCAGCTTTGCACTATGCAGTGGAATTATTTGAAGGATTGAAGGCATTTCGA
GGAGTAGATAATAAAATTCGACTGTTTCAGCCAAACCTCAACATGGATAGAATGTATCGC
TCTGCTGTGAGGGCAACTCTGCCGGTATTTGACAAAGAAGAGCTCTTAGAGTGTATTCAA
CAGCTTGTGAAATTGGATCAAGAATGGGTCCCATATTCAACATCTGCTAGTCTGTATATT
CGTCCTGCATTCATTGGAACTGAGCCTTCTCTTGGAGTCAAGAAGCCTACCAAAGCCCTG
CTCTTTGTACTCTTGAGCCCAGTGGGACCTTATTTTTCAAGTGGAACCTTTAATCCAGTG
TCCCTGTGGGCCAATCCCAAGTATGTAAGAGCCTGGAAAGGTGGAACTGGGGACTGCAAG
ATGGGAGGGAATTACGGCTCATCTCTTTTTGCCCAATGTGAAGACGTAGATAATGGGTGT
CAGCAGGTCCTGTGGCTCTATGGCAGAGACCATCAGATCACTGAAGTGGGAACTATGAAT
CTTTTTCTTTACTGGATAAATGAAGATGGAGAAGAAGAACTGGCAACTCCTCCACTAGAT
GGCATCATTCTTCCAGGAGTGACAAGGCGGTGCATTCTGGACCTGGCACATCAGTGGGGT
GAATTTAAGGTGTCAGAGAGATACCTCACCATGGATGACTTGACAACAGCCCTGGAGGGG
AACAGAGTGAGAGAGATGTTTAGCTCTGGTACAGCCTGTGTTGTTTGCCCAGTTTCTGAT
ATACTGTACAAAGGCGAGACAATACACATTCCAACTATGGAGAATGGTCCTAAGCTGGCA
AGCCGCATCTTGAGCAAATTAACTGATATCCAGTATGGAAGAGAAGAGAGCGACTGGACA
ATTGTGCTATCCTGA

# Drug_Target_4_General_Function:
Amino acid transport and metabolism

# Drug_Target_4_General_References:
8692959	Schuldiner O, Eden A, Ben-Yosef T, Yanuka O, Simchen G, Benvenisty N: ECA39, a conserved gene regulated by c-Myc in mice, is involved in G1/S cell cycle regulation in yeast. Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7143-8.

# Drug_Target_4_HGNC_ID:
HGNC:976

# Drug_Target_4_HPRD_ID:
00216

# Drug_Target_4_ID:
574

# Drug_Target_4_Locus:
12pter-q12

# Drug_Target_4_Molecular_Weight:
42953

# Drug_Target_4_Name:
Branched-chain-amino-acid aminotransferase, cytosolic

# Drug_Target_4_Number_of_Residues:
386

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF01063	Aminotran_4

# Drug_Target_4_Protein_Sequence:
>Branched-chain-amino-acid aminotransferase, cytosolic
MKDCSNGCSAECTGEGGSKEVVGTFKAKDLIVTPATILKEKPDPNNLVFGTVFTDHMLTV
EWSSEFGWEKPHIKPLQNLSLHPGSSALHYAVELFEGLKAFRGVDNKIRLFQPNLNMDRM
YRSAVRATLPVFDKEELLECIQQLVKLDQEWVPYSTSASLYIRPTFIGTEPSLGVKKPTK
ALLFVLLSPVGPYFSSGTFNPVSLWANPKYVRAWKGGTGDCKMGGNYGSSLFAQCEAVDN
GCQQVLWLYGEDHQITEVGTMNLFLYWINEDGEEELATPPLDGIILPGVTRRCILDLAHQ
WGEFKVSERYLTMDDLSTALEGNRVREMFGSGTACVVCPVSDILYKGETIHIPTMENGPK
LASRILSKLTDIQYGREESDWTIVLS

# Drug_Target_4_Reaction:
L-leucine + 2-oxoglutarate = 4-methyl-2-oxopentanoate + L-glutamate

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine

# Drug_Target_4_SwissProt_ID:
P54687

# Drug_Target_4_SwissProt_Name:
BCAT1_HUMAN

# Drug_Target_4_Synonyms:
BCAT(c)
EC 2.6.1.42
ECA39 protein

# Drug_Target_4_Theoretical_pI:
4.95

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Isoform A:Mitochondrion. Isoform B:Cytoplasm

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
12670965	Berger BJ, English S, Chan G, Knodel MH: Methionine regeneration and aminotransferases in Bacillus subtilis, Bacillus cereus, and Bacillus anthracis. J Bacteriol. 2003 Apr;185(8):2418-31.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
BCAT2

# Drug_Target_5_GenBank_ID_Gene:
U68418

# Drug_Target_5_GenBank_ID_Protein:
2342862

# Drug_Target_5_GeneCard_ID:
BCAT2

# Drug_Target_5_Gene_Name:
BCAT2

# Drug_Target_5_Gene_Sequence:
>1179 bp
ATGGCCGCAGCCGCTCTGGGGCAGATCTGGGCACGAAAGCTTCTCTCTGTCCCTTGGCTT
CTGTGTGGTCCCAGAAGATATGCCTCCTCCAGTTTCAAGGCTGCAGACCTGCAGCTGGAA
ATGACACAGAAGCCTCATAAGAAGCCTGGCCCCGGCGAGCCCCTGGTGTTTGGGAAGACA
TTTACCGACCACATGCTGATGGTGGAATGGAATGACAAGGGCTGGGGCCAGCCCCGAATC
CAGCCCTTCCAGAACCTCACGCTGCACCCAGCCTCCTCCAGCCTCCACTACTCCCTGCAG
CTGTTTGAGGGCATGAAGGCGTTCAAAGGCAAAGACCAGCAGGTGCGCCTCTTCCGCCCC
TGGCTCAACATGGACCGGATGCTGCGCTCAGCCATGCGCCTGTGCCTGCCGAGTTTCGAC
AAGCTGGAGTTGCTGGAGTGCATCCGCCGGCTCATCGAAGTGGACAAGGACTGGGTCCCC
GATGCCGCCGGCACCAGCCTCTATGTGCGGCCTGTGCTCATTGGGAACGAGCCCTCGCTG
GGTGTCAGCCAGCCCAGGCGCGCGCTCCTGTTCGTCATTCTCTGCCCAGTGGGTGCCTAC
TTCCCTGGAGGCTCCGTGACCCCGGTCTCCCTCCTGGCCGACCCAGCCTTCATCCGGGCC
TGGGTGGGCGGGGTCGGCAACTACAAGTTAGGTGGGAATTATGGGCCCACCGTGTTAGTG
CAACAGGAGGCACTCAAGCGGGGCTGTGAACAGGTCCTCTGGCTGTATGGGCCCGACCAC
CAGCTCACCGAGGTGGGAACCATGAACATCTTTGTCTACTGGACCCACGAAGATGGGGTG
CTGGAGCTGGTGACGCCCCCGCTGAATGGTGTTATCCTGCCTGGAGTGGTCAGACAGAGT
CTACTGGACATGGCTCAGACCTGGGGTGAGTTCCGGGTGGTGGAGCGCACGATCACCATG
AAGCAGTTGCTGCGGGCCTTGGAGGAGGGCCGCGTGCGGGAAGTCTTTGGCTCGGGCACC
GCTTGCCAGGTCTGCCCAGTGCACCGAATCCTGTACAAAGACAGGAACCTCCATATTCCC
ACCATGGAAAATGGGCCTGAGCTGATCCTCCGCTTCCAGAAGGAGCTGAAGGAGATCCAG
TACGGAATCAGAGCCCACGAGTGGATGTTCCCGGTGTGA

# Drug_Target_5_General_Function:
Amino acid transport and metabolism

# Drug_Target_5_General_References:
11170829	Than NG, Sumegi B, Than GN, Bellyei S, Bohn H: Molecular cloning and characterization of placental tissue protein 18 (PP18a)/human mitochondrial branched-chain aminotransferase (BCATm) and its novel alternatively spliced PP18b variant. Placenta. 2001 Feb-Mar;22(2-3):235-43.
11264579	Yennawar N, Dunbar J, Conway M, Hutson S, Farber G: The structure of human mitochondrial branched-chain aminotransferase. Acta Crystallogr D Biol Crystallogr. 2001 Apr;57(Pt 4):506-15.
12269802	Yennawar NH, Conway ME, Yennawar HP, Farber GK, Hutson SM: Crystal structures of human mitochondrial branched chain aminotransferase reaction intermediates: ketimine and pyridoxamine phosphate forms. Biochemistry. 2002 Oct 1;41(39):11592-601.
8702755	Eden A, Simchen G, Benvenisty N: Two yeast homologs of ECA39, a target for c-Myc regulation, code for cytosolic and mitochondrial branched-chain amino acid aminotransferases. J Biol Chem. 1996 Aug 23;271(34):20242-5.
9165094	Bledsoe RK, Dawson PA, Hutson SM: Cloning of the rat and human mitochondrial branched chain aminotransferases (BCATm). Biochim Biophys Acta. 1997 Apr 25;1339(1):9-13.

# Drug_Target_5_HGNC_ID:
HGNC:977

# Drug_Target_5_HPRD_ID:
00217

# Drug_Target_5_ID:
795

# Drug_Target_5_Locus:
19q13

# Drug_Target_5_Molecular_Weight:
44288

# Drug_Target_5_Name:
Branched-chain-amino-acid aminotransferase, mitochondrial

# Drug_Target_5_Number_of_Residues:
392

# Drug_Target_5_PDB_ID:
1KTA

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF01063	Aminotran_4

# Drug_Target_5_Protein_Sequence:
>Branched-chain-amino-acid aminotransferase, mitochondrial precursor
MAAAALGQIWARKLLSVPWLLCGPRRYASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKT
FTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRP
WLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSL
GVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLV
QQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQS
LLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIP
TMENGPELILRFQKELKEIQYGIRAHEWMFPV

# Drug_Target_5_Reaction:
L-leucine + 2-oxoglutarate = 4-methyl-2-oxopentanoate + L-glutamate

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine. May also function as a transporter of branched chain alpha-keto acids

# Drug_Target_5_SwissProt_ID:
O15382

# Drug_Target_5_SwissProt_Name:
BCAT2_HUMAN

# Drug_Target_5_Synonyms:
BCAT(m)
Branched-chain-amino-acid aminotransferase, mitochondrial precursor
EC 2.6.1.42
PP18
Placental protein 18

# Drug_Target_5_Theoretical_pI:
8.82

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Cytoplasm

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
12783542	Wang P, Tang Y, Tirrell DA: Incorporation of trifluoroisoleucine into proteins in vivo. J Am Chem Soc. 2003 Jun 11;125(23):6900-6.
12788342	Crasto CF, Forrest AK, Karoli T, March DR, Mensah L, O'Hanlon PJ, Nairn MR, Oldham MD, Yue W, Banwell MG, Easton CJ: Synthesis and activity of analogues of the isoleucyl tRNA synthetase inhibitor SB-203207. Bioorg Med Chem. 2003 Jul 3;11(13):2687-94.
14672940	Fukunaga R, Fukai S, Ishitani R, Nureki O, Yokoyama S: Crystal structures of the CP1 domain from Thermus thermophilus isoleucyl-tRNA synthetase and its complex with L-valine. J Biol Chem. 2004 Feb 27;279(9):8396-402. Epub 2003 Dec 12.
15163798	Pezo V, Metzgar D, Hendrickson TL, Waas WF, Hazebrouck S, Doring V, Marliere P, Schimmel P, De Crecy-Lagard V: Artificially ambiguous genetic code confers growth yield advantage. Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8593-7. Epub 2004 May 26.
16397872	Mock ML, Michon T, van Hest JC, Tirrell DA: Stereoselective incorporation of an unsaturated isoleucine analogue into a protein expressed in E. coli. Chembiochem. 2006 Jan;7(1):83-7.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
IARS

# Drug_Target_6_GenBank_ID_Gene:
D28473

# Drug_Target_6_GenBank_ID_Protein:
551622

# Drug_Target_6_GeneCard_ID:
IARS

# Drug_Target_6_Gene_Name:
IARS

# Drug_Target_6_Gene_Sequence:
>3801 bp
ATGAGCAACAAAATGCTTCAACAAGTTCCAGAAAACATAAATTTTCCTGCTGAAGAAGAG
AAAATCTTGGAGTTTTGGACTGAATTTAATTGTTTTCAGGAATGCTTAAAGCAATCAAAA
CATAAACCAAAATTTACCTTCTATGATGGTCCTCCTTTTGCAACTGGACTGCCTCACTAT
GGACATATACTTGCGGGTACAATTAAAGATATAGTTACAAGATATGCTCACCAGAGTGGG
TTTCATGTTGACAGAAGATTTGGATGGGATTGCCATGGCTTACCTGTGGAATATGAAATT
GATAAGACACTGGGAATCAGAGGACCAGAGGATGTGGCCAAAATGGGGATTACAGAGTAT
AACAATCAGTGCCGAGCAATTGTGATGAGATATTCTGCTGAGTGGAAGTCTACTGTTAGC
AGACTTGGCCGATGGATTGACTTTGACAATGACTATAAAACTCTGTATCCACAATTCATG
GAATCAGTCTGGTGGGTCTTCAAACAACTCTATGATAAAGGCCTTGTTTATAGAGGTGTG
AAAGTCATGCCCTTCTCTACGGCATGTAACACTCCACTTTCCAACTTCGAGTCACACCAG
AATTATAAGGATGTTCAAGATCCTTCAGTATTTGTAACTTTCCCTTTGGAAGAAGATGAA
ACTGTATCTTTAGTTGCTTGGACAACCACTCCCTGGACTCTACCTAGTAACCTTGCTGTG
TGTGTTAATCCAGAAATGCAATATGTGAAAATTAAAGATGTTGCCAGAGGACGATTACTC
ATTTTAATGGAAGCCAGATTGTCAGCCCTCTATAAATTGGAGAGTGACTATGAGATCCTT
GAAAGATTTCCTGGTGCCTATCTTAAAGGCAAGAAGTACAGGCCCCTGTTTGACTATTTC
CTGAAGTGTAAAGAGAATGGCGCTTTCACTGTGCTTGTTGACAACTATGTGAAGGAAGAA
GAAGGCACAGGGGTTGTCCACCAAGCTCCTTACTTCGGTGCTGAGGACTATCGGGTCTGT
ATGGACTTTAACATTATTCGGAAAGACTCACTCCCTGTTTGCCCTGTGGATGCTTCAGGC
TGCTTCACAACGGAGGTGACAGATTTCGCAGGACAGTATGTGAAGGATGCTGACAAAAGT
ATCATCAGGACTTTGAAGGAACAAGGCCGACTTCTGGTTGCCACCACCTTCACTCACAGC
TACCCTTTTTGCTGGAGATCAGACACTCCTCTAATTTACAAAGCAGTGCCCAGCTGGTTT
GTGCGAGTGGAGAACATGGTGGACCAGCTCCTAAGGAACAATGACCTGTGCTACTGGGTC
CCAGAGTTGGTACGAGAAAAACGATTTGGAAATTGGCTGAAAGATGCACGTGACTGGACA
ATTTCCAGAAACAGATACTGGGGCACCCCCATCCCACTGTGGGTCAGCGATGACTTTGAG
GAGGTGGTATGCATTGGGTCAGTGGCGGAACTTGAAGAACTGTCAGGAGCAAAGATCTCA
GATCTCCACAGAGAGAGTGTTGACCACCTGACCATTCCTTCACGCTGTGGGAAGGGATCC
TTGCACCGCATCTCTGAAGTGTTTGACTGTTGGTTTGAGAGTGGCAGCATGCCCTATGCT
CAGGTTCATTACCCGTTTGAAAACAAGAGGGAGTTTGAGGATGCTTTTCCTGCAGATTTC
ATTGCCGAGGGCATCGACCAAACCAGAGGATGGTTTTATACCCTGCTGGTGCTGGCCACG
GCCCTCTTTGGACAACCGCCTTTCAAGAACGTAATTGTGAATGGGCTTGTCCTGGCAAGT
GATGGCCAAAAAATGAGCAAACGGAAAAAGAATTATCCAGATCCAGTTTCCATCATCCAG
AAGTATGGTGCTGATGCCCTCAGATTATATCTGATTAACTCCCCTGTGGTGAGAGCAGAA
AACCTCCGCTTTAAAGAAGAGGGTGTGCGGGACGTCCTTAAGGATGTACTGCTCCCATGG
TACAATGCCTATCGCTTCTTAATCCAGAACGTTCTGAGGCTCCAGAAGGAGGAAGAAATA
GAATTTCTCTACAATGAGAACACGGTTAGAGAAAGCCCCAACATTACAGACCGGTGGATC
CTGTCCTTCATGCAGTCTCTCATTGGCTTCTTTGAGACTGAAATGGCAGCTTATAGGCTT
TATACTGTGGTGCCTCGCCTGGTCAAGTTTGTAGATATTCTGACCAATTGGTATGTTAGA
ATGAACCGCAGAAGATTAAAGGGTGAAAATGGGATGGAGGATTGTGTCATGGCCCTAGAA
ACCTTGTTTAGTGTTCTGCTTTCTCTTTGCAGACTTATGGCTCCCTACACACCTTTTCTC
ACTGAATTGATGTACCAGAATCTAAAGGTGCTGATTGACCCTGTTTCTGTTCAGGACAAG
GACACACTCAGCATTCACTACCTCATGCTGCCCCGTGTTCGAGAAGAATTGATTGACAAG
AAAACAGAGAGTGCAGTATCTCAGATGCAGTCTGTGATTGAACTTGGAAGAGTGATCAGA
GACCGAAAAACTATTCCCATAAAGTATCCTTTGAAAGAAATTGTGGTTATCCATCAAGAT
CCAGAAGCTCTTAAAGATATCAAGTCTTTGGAGAAGTATATCATTGAGGAACTCAATGTT
CGAAAAGTTACACTGTCTACAGATAAAAACAAGTATGGCATTCGGCTAAGGGCAGAACCA
GATCACATGGTCCTGGGGAAGCGTCTGAAGGGAGCCTTTAAGGCAGTGATGACGTCCATC
AAGCAGTTGAGCAGTGAGGAGCTGGAGCAGTTCCAGAAGACTGGGACCATTGTTGTGGAA
GGCCATGAATTGCACGATGAAGACATCCGCCTCATGTACACCTTTGATCAGGCCACAGGT
GGGACTGCGCAATTTGAAGCACACTCAGATGCTCAGGCTTTGGTCCTCTTAGATGTCACT
CCTGACCAGTCAATGGTAGATGAAGGAATGGCTCGGGAAGTCATCAATCGCATACAGAAA
CTTCGCAAAAAGTGCAATCTGGTTCCAACTGATGAAATCACAGTGTACTATAAAGCAAAG
TCTGAAGGAACATATCTGAATAGTGTTATTGAAAGCCACACAGAGTTCATATTTACCACC
ATAAAGGCTCCCTTGAAACCATATCCAGTTTCTCCATCGGATAAAGTCCTTATTCAAGAA
AAAACACAGTTGAAGGGATCTGAACTGGAAATTACACTCACCAGAGGATCTTCCCTTCCT
GGTCCTGCTTGTGCATATGTCAATCTTAACATTTGTGCAAATGGCAGTGAACAAGGTGGA
GTATTGCTCCTGGAAAATCCAAAAGGTGACAATAGGTTGGACCTTTTAAAGCTGAAGAGT
GTTGTCACTAGCATTTTTGGTGTGAAAAATACAGAGCTGGCTGTCTTCCATGATGAAACA
GAAATACAAAACCAAACTGACTTACTGAGTCTTAGTGGAAAAACACTTTGTGTGACTGCA
GGATCGGCTCCCTCTCTGATCAACAGTTCTAGTACTCTTCTTTGTCAGTATATCAACCTA
CAGCTCCTGAATGCAAAGCCACAAGAGTGTTTAATGGGGACAGTGGGCACTCTCCTGCTT
GAAAACCCACTTGGGCAGAATGGACTCACCCACCAAGGTCTTCTGTATGAAGCAGCCAAG
GTGTTTGGCCTTCGGAGCAGGAAGCTAAAGCTGTTTCTGAATGAGACCCAAACGCAGGAA
ATTACAGAAGACATCCCCGTGAAGACTTTGAATATGAAGACTGTGTATGTTTCTGTGTTA
CCAACAACAGCAGACTTCTAG

# Drug_Target_6_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_6_General_References:
7721108	Nichols RC, Raben N, Boerkoel CF, Plotz PH: Human isoleucyl-tRNA synthetase: sequence of the cDNA, alternative mRNA splicing, and the characteristics of an unusually long C-terminal extension. Gene. 1995 Apr 3;155(2):299-304.
8052601	Shiba K, Suzuki N, Shigesada K, Namba Y, Schimmel P, Noda T: Human cytoplasmic isoleucyl-tRNA synthetase: selective divergence of the anticodon-binding domain and acquisition of a new structural unit. Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7435-9.

# Drug_Target_6_HGNC_ID:
HGNC:5330

# Drug_Target_6_HPRD_ID:
02832

# Drug_Target_6_ID:
546

# Drug_Target_6_Locus:
9q21

# Drug_Target_6_Molecular_Weight:
144960

# Drug_Target_6_Name:
Isoleucyl-tRNA synthetase, cytoplasmic

# Drug_Target_6_Number_of_Residues:
1266

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00133	tRNA-synt_1
PF08264	Anticodon_1

# Drug_Target_6_Protein_Sequence:
>Isoleucyl-tRNA synthetase, cytoplasmic
MSNKMLQQVPENINFPAEEEKILEFWTEFNCFQECLKQSKHKPKFTFYDGPPFATGLPHY
GHILAGTIKDIVTRYAHQSGFHVDRRFGWDCHGLPVEYEIDKTLGIRGPEDVAKMGITEY
NNQCRAIVMRYSAEWKSTVSRLGRWIDFDNDYKTLYPQFMESVWWVFKQLYDKGLVYRGV
KVMPFSTACNTPLSNFESHQNYKDVQDPSVFVTFPLEEDETVSLVAWTTTPWTLPSNLAV
CVNPEMQYVKIKDVARGRLLILMEARLSALYKLESDYEILERFPGAYLKGKKYRPLFDYF
LKCKENGAFTVLVDNYVKEEEGTGVVHQAPYFGAEDYRVCMDFNIIRKDSLPVCPVDASG
CFTTEVTDFAGQYVKDADKSIIRTLKEQGRLLVATTFTHSYPFCWRSDTPLIYKAVPSWF
VRVENMVDQLLRNNDLCYWVPELVREKRFGNWLKDARDWTISRNRYWGTPIPLWVSDDFE
EVVCIGSVAELEELSGAKISDLHRESVDHLTIPSRCGKGSLHRISEVFDCWFESGSMPYA
QVHYPFENKREFEDAFPADFIAEGIDQTRGWFYTLLVLATALFGQPPFKNVIVNGLVLAS
DGQKMSKRKKNYPDPVSIIQKYGADALRLYLINSPVVRAENLRFKEEGVRDVLKDVLLPW
YNAYRFLIQNVLRLQKEEEIEFLYNENTVRESPNITDRWILSFMQSLIGFFETEMAAYRL
YTVVPRLVKFVDILTNWYVRMNRRRLKGENGMEDCVMALETLFSVLLSLCRLMAPYTPFL
TELMYQNLKVLIDPVSVQDKDTLSIHYLMLPRVREELIDKKTESAVSQMQSVIELGRVIR
DRKTIPIKYPLKEIVVIHQDPEALKDIKSLEKYIIEELNVRKVTLSTDKNKYGIRLRAEP
DHMVLGKRLKGAFKAVMTSIKQLSSEELEQFQKTGTIVVEGHELHDEDIRLMYTFDQATG
GTAQFEAHSDAQALVLLDVTPDQSMVDEGMAREVINRIQKLRKKCNLVPTDEITVYYKAK
SEGTYLNSVIESHTEFIFTTIKAPLKPYPVSPSDKVLIQEKTQLKGSELEITLTRGSSLP
GPACAYVNLNICANGSEQGGVLLLENPKGDNRLDLLKLKSVVTSIFGVKNTELAVFHDET
EIQNQTDLLSLSGKTLCVTAGSAPSLINSSSTLLCQYINLQLLNAKPQECLMGTVGTLLL
ENPLGQNGLTHQGLLYEAAKVFGLRSRKLKLFLNETQTQEITEDIPVKTLNMKTVYVSVL
PTTADF

# Drug_Target_6_Reaction:
ATP + L-isoleucine + tRNAIle = AMP + diphosphate + L-isoleucyl-tRNAIle

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Not Available

# Drug_Target_6_SwissProt_ID:
P41252

# Drug_Target_6_SwissProt_Name:
SYIC_HUMAN

# Drug_Target_6_Synonyms:
EC 6.1.1.5
IRS
IleRS
Isoleucine--tRNA ligase

# Drug_Target_6_Theoretical_pI:
6.10

# Drug_Target_6_Transmembrane_Regions:
None

#END_DRUGCARD DB00167
